Update on idiopathic inflammatory myopathies

被引:88
作者
Briani, C.
Doria, A.
Sarzi-Puttini, P.
Dalakas, M. C.
机构
[1] Univ Padua, Dept Neurosci, I-35128 Padua, Italy
[2] Univ Padua, Div Rheumatol, I-35100 Padua, Italy
[3] L Sacco Univ Hosp, Rheumatol Unit, Dept Rheumatol, Milan, Italy
[4] NINDS, Neuromuscular Dis Sect, NIH, Bethesda, MD 20892 USA
关键词
polymyositis; dermatomyositis; inclusion body myositis; cancer; connective tissue diseases;
D O I
10.1080/08916930600622132
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The inflammatory myopathies are a group of acquired diseases, characterized by an inflammatory infiltrate of the skeletal muscle. On the basis of clinical, immuno-pathological and demographic features, three major diseases can be identified: dermatomyositis (DM); polymyositis (PM); and inclusion body myositis (IBM). New diagnostic criteria have recently been introduced, which are crucial for discriminating between the three different subsets of inflammatory myopathies and for excluding other disorders. DM is a complement-mediated microangiopathy affecting skin and muscle. PM and IBM are T cell-mediated disorders, where CD8-positive cytotoxic T cells invade muscle fibres expressing MHC class I antigens, thus leading to fibre necrosis. In IBM, vacuolar formation with amyloid deposits are also present. This article summarizes the main clinical, laboratory, electrophysiological, immunological and histologic features as well as the therapeutic options of the inflammatory myopathies.
引用
收藏
页码:161 / 170
页数:10
相关论文
共 87 条
[1]  
Alexanderson H, 2000, SCAND J RHEUMATOL, V29, P295
[2]   Proposed pathogenetic cascade of inclusion-body myositis:: importance of amyloid-β, misfolded proteins, predisposing genes, and aging [J].
Askanas, V ;
Engel, WK .
CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (06) :737-744
[3]  
BENBASSAT J, 1980, ISRAEL J MED SCI, V16, P197
[4]   POLYMYOSITIS AND DERMATOMYOSITIS .2. [J].
BOHAN, A ;
PETER, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (08) :403-407
[5]   POLYMYOSITIS AND DERMATOMYOSITIS .1. [J].
BOHAN, A ;
PETER, JB .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (07) :344-347
[6]   Autoantibody profiles in the sera of European patients with myositis [J].
Brouwer, R ;
Hengstman, GJD ;
Egberts, WV ;
Ehrfeld, H ;
Bozic, B ;
Ghirardello, A ;
Grondal, G ;
Hietarinta, M ;
Isenberg, D ;
Kalden, JR ;
Lundberg, I ;
Moutsopoulos, H ;
Roux-Lombard, P ;
Vencovsky, J ;
Wikman, A ;
Seelig, HP ;
van Engelen, BGM ;
van Venrooij, WJ .
ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (02) :116-123
[7]   Dermatomyositis [J].
Callen, JP .
LANCET, 2000, 355 (9197) :53-57
[8]  
CHERIN P, 1995, CLIN EXP RHEUMATOL, V13, P270
[9]   Intravenous immunoglobulin for dysphagia of inclusion body myositis [J].
Cherin, P ;
Pelletier, S ;
Teixeira, A ;
Laforet, P ;
Simon, A ;
Herson, S ;
Eymard, B .
NEUROLOGY, 2002, 58 (02) :326-327
[10]  
CHEVREL G, IN PRESS AUTOIMMUNIT